
CLAIMS

1. A compound of formula (I) :



(I)


wherein :

Z is COOQ;

Q is H;

m is 4;

R is selected from the group consisting of:





with X being independently Br or I;;


Wis -(C=O)-NR^2-;


$R^2$is H;


Ch is a chelating agent optionally comprising a metal or a radiometal with Ch being selected from the group consisting of:













; and




;

and pharmaceutically acceptable salts thereof.


2. The compound of formula (I) according to claim 1, wherein the compound is a compound of formula (Ia), (Ib), (Ic) or (Id):




(Ia)



(Ib)




(Ic)



(Id).

.

3. The compound of formula (I) according to claims 1 or 2, wherein R is




.

4. The compound of formula (I) according to any one of claims 1 to 3, wherein Ch comprises a metal selected from Y, Lu, Tc, Zr, In, Sm, Re, Cu, Pb, Ac, Bi, Al, Ga, Re, Ho and Sc.

5. The compound of formula (I) according to claim 4, wherein the metal is a radiometal selected from ^{68}Ga, ^{64}Cu, ^{86}Y, ^{90}Y, ^{89}Zr, ^{111}In, ^{99m}Tc, ^{177}Lu, ^{153}Sm, ^{186}Re, ^{188}Re, ^{67}Cu, ^{212}Pb, ^{225}Ac, ^{213}Bi, ^{212}Bi, ^{212}Pb, ^{67}Ga, ^{203}Pb, ^{47}Sc, and ^{166}Ho.


6. The compound of formula (I) according to any one of claims 1 to 5, wherein the compound is distributed in the body of a tumor bearing animal or human in such a way that, 1 h after the intravenous injection of the compound, the tumor-to-kidney ratio is at least 5.

7. The compound of formula (I) according to any of claims 1 to 6, wherein the compound is a compound of formula (II):




(II).

8. The compound of formula (I) according to any of claims 1 to 7, wherein the compound is a compound of formula (III):



(III)

9. The compound of formula (I) according to any of claims 1 to 7, wherein the compound is a compound of formula (IV):



(IV)

10. A pharmaceutical composition comprising a compound of formula (I) according to any of claims 1 to 6, a compound of formula (II) according to claim 7, a compound of formula (III) according to claim 8, or a compound of formula (IV) according to claim 9, and at least one pharmaceutically acceptable carrier.